10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics has disclosed Total Current Liabilities across 9 years of filings, most recently posting $118.5 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 5.6% year-over-year to $118.5 million; the TTM figure through Jun 2026 stood at $118.5 million (up 5.6% YoY), while the FY2025 annual figure was $153.5 million, up 30.45% from the prior year.
• Total Current Liabilities came in at $118.5 million for Q2 2026 at 10x Genomics, up from $113.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $153.5 million in Q4 2025 to a low of $94.4 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $118.0 million, with a median of $115.6 million recorded in 2024.
• Year-over-year, Total Current Liabilities decreased 21.65% in 2022 and soared 30.45% in 2025.
• Over 5 years, Total Current Liabilities stood at $131.0 million in 2022, then dropped by 2.9% to $127.2 million in 2023, then decreased by 7.49% to $117.6 million in 2024, then jumped by 30.45% to $153.5 million in 2025, then retreated by 22.77% to $118.5 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $118.5 million in Q2 2026, $113.6 million in Q1 2026, and $153.5 million in Q4 2025.